18
May

Boehringer Ingelheim has made a quick decision about Pharmaxis’ non-alcoholic steatohepatitis (NASH) drug, striking a $250 million deal to buy the Phase I asset just two months after inking an option to acquire the program.

…read more

Source: Boehringer strikes $250M deal for Phase I NASH drug

    

0 No comments